Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
QNRX
QNRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
QNRX News
Quoin Pharmaceuticals Q1 Earnings Beat Expectations
4d ago
seekingalpha
Quoin Pharmaceuticals Provides Clinical Update on QRX009 Development
Apr 29 2026
NASDAQ.COM
Quoin Pharmaceuticals Initiates Multiple Clinical Studies for QRX009
Apr 28 2026
Newsfilter
Quoin Pharmaceuticals Initiates Multiple Clinical Studies for QRX009
Apr 28 2026
Newsfilter
Biotech Landscape Update: Regulatory Approvals and Mergers
Mar 27 2026
NASDAQ.COM
Quoin Pharmaceuticals Q4 Earnings Beat Expectations
Mar 26 2026
seekingalpha
Quoin Pharmaceuticals Provides Clinical Update on QRX003
Mar 26 2026
NASDAQ.COM
Quoin Pharmaceuticals Shares Surge 20% on FDA Feedback for QRX003
Mar 25 2026
stocktwits
QNRX Shares Jump 20% in Pre-Market Trading – FDA's Comments on Netherton Syndrome Treatment?
Mar 25 2026
stocktwits
Quoin Pharmaceuticals Advances FDA Approval Process for QRX003
Mar 25 2026
Newsfilter
Quoin Pharmaceuticals Advances NETHERTON NOW Awareness Campaign
Feb 26 2026
Newsfilter
Quoin Pharmaceuticals Files for Breakthrough Designation for QRX003, Potential First Treatment for Netherton Syndrome
Jan 20 2026
Globenewswire
Quoin Pharmaceuticals Stock Rises 21% Following Topical Rapamycin Achievement
Nov 11 2025
NASDAQ.COM
US Stocks Show Varied Performance; Sea Shares Rise Following Q3 Earnings Report
Nov 11 2025
Benzinga
Quoin Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for QRX003 in Netherton Syndrome
Oct 21 2025
Newsfilter
What’s Driving Quoin Pharmaceuticals' Pre-market Surge?
Oct 21 2025
NASDAQ.COM
Show More News
